1. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Issue 10367 (3rd December 2022) Authors: Schlaich, Markus P; Bellet, Marc; Weber, Michael A; Danaietash, Parisa; Bakris, George L; Flack, John M; Dreier, Roland F; Sassi-Sayadi, Mouna; Haskell, Lloyd P; Narkiewicz, Krzysztof; Wang, Ji-Guang; Reid, Christopher; Schlaich, Markus; Katz, Ivor; Ajani, Andrew; Biswas, Sinjini; Esler, Murray; ... Journal: Lancet Issue: Volume 400:Issue 10367(2022) Page Start: 1927 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗